The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The clinical use of MRD in CLL and challenges in this space
Alexey V. Danilov, MD, PhD, City of Hope, Duarte, CA, shares some insights into the clinical use of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL). Prof. Danilov first highlights methods used in MRD testing, and then goes on to explain the challenges with implementing MRD outside of a clinical trial setting, and the need for more research in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
